Sayuri Kawasaki, Yukinao Sakai, Shinsuke Harasawa, Akihito Inatsu, Yoshiaki Kubota, Akio Hirama, Tetsuya Kashiwagi, Masato Iwabu

The efficacy and safety of ivabradine hydrochloride in hemodialysis patients with chronic heart failure

  • Nephrology
  • Hematology
Save to CiteDrive Show PDF

AbstractIntroductionThere is little evidence for ivabradine hydrochloride in patients undergoing hemodialysis.MethodsIn this open‐label prospective interventional trial of hemodialysis patients with chronic heart failure, during 12 weeks of treatment, changes in Heart rate (HR), frequency of dialysis‐related hypotension were examined, and we investigated health‐related quality of life (HR‐QOL) and adverse effects.Results18 patients from 6 facilities were enrolled in the study. HR significantly decreased over time, from 87 ± 12.61/min at baseline to 75.85 ± 8.91/min (p = 0.0003), and systolic blood pressure also increased significantly (p < 0.0001). The frequency of dialysis‐related hypotension was markedly reduced (p = 0.0001). The HR‐QOL survey showed significant improvements in Social Functioning among others (p = 0.0178). No specific adverse events occurred.ConclusionIvabradine hydrochloride improved dialysis‐related hypotension. Furthermore, the HR‐QOL improvement effect were suggested. These results demonstrated the safety and effectiveness of ivabradine hydrochloride.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive